Nivolumab or Ipilimumab ± Azacitidine in Treatment-Naive or HMA-Failed Myelodysplastic Syndromes

December 3-6, 2016; San Diego, California
Preliminary phase II data suggest promising activity of single-agent ipilimumab and nivolumab plus azacitidine in a molecularly high-risk population of MDS patients.
Format: Microsoft PowerPoint (.ppt)
File Size: 655 KB
Released: December 9, 2016

Acknowledgements

This activity is supported by educational grants from
Amgen
Celgene Corporation
Incyte
Merck & Co., Inc.
Seattle Genetics

Related Content

Download this slideset to review the latest clinical data informing optimal management strategies for follicular lymphoma

Emily Bucholtz Headshot Emily Bucholtz, RPh Nichole Fisher Headshot Nichole Fisher, RN, BSN Jeff P. Sharman, MD Released: October 14, 2020

Download this ExpressPoints slideset for a quick summary of the latest clinical data informing optimal management of follicular lymphoma

Emily Bucholtz Headshot Emily Bucholtz, RPh Nichole Fisher Headshot Nichole Fisher, RN, BSN Jeff P. Sharman, MD Released: October 14, 2020

In this slideset from Clinical Care Options (CCO), experts review treatment options after BTK inhibitor– and venetoclax for patients with CLL.

Jeremy S. Abramson, MD, MMSc Released: October 14, 2020

Expert insight commentary from Clinical Care Options (CCO) on use of luspatercept for the treatment of anemia in myelodysplastic syndromes (MDS) patients

Guillermo Garcia-Manero, MD Released: October 14, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue